What is the equivalent dose of Lantus (insulin glargine) if a patient is currently taking Toujeo (insulin glargine) 36 units subcutaneously daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Converting from Toujeo 36 Units to Lantus: Dose Equivalence

When converting a patient from Toujeo 36 units subcutaneous daily to Lantus, the equivalent dose should be 36 units of Lantus subcutaneous daily (1:1 conversion).

Rationale for Dose Conversion

Toujeo (insulin glargine U-300) and Lantus (insulin glargine U-100) are both long-acting basal insulin analogs containing the same active ingredient (insulin glargine), but at different concentrations:

  • Toujeo contains 300 units/mL (U-300)
  • Lantus contains 100 units/mL (U-100)

Despite the concentration difference, clinical guidelines support a 1:1 unit conversion when switching between these insulins:

  • The same number of units should be prescribed when converting between Toujeo and Lantus 1
  • The total daily insulin dose remains the same, with the only change being the insulin formulation 1

Implementation Considerations

When converting from Toujeo to Lantus, consider these important factors:

  • Timing of administration: Lantus should be administered at the same time of day as the patient was taking Toujeo
  • Blood glucose monitoring: More frequent monitoring is recommended for 3-7 days after conversion
  • Dose adjustments: May be needed after transition based on blood glucose patterns
  • Patient education: Explain that while the number of units remains the same, the volume of insulin will be different due to the concentration change

Potential Clinical Differences

Despite the 1:1 unit conversion, be aware of potential differences in clinical effect:

  • Lantus may have a slightly different pharmacokinetic profile compared to Toujeo
  • Toujeo typically has a more prolonged and stable glucose-lowering effect with less day-to-day variability 2
  • Patients may experience slightly different glycemic control or hypoglycemia risk after conversion

Monitoring and Follow-up

After converting to Lantus 36 units daily:

  • Monitor fasting blood glucose levels daily for the first week
  • Adjust Lantus dose as needed based on fasting glucose patterns:
    • FBG ≥180 mg/dL: Increase by 6-8 units
    • FBG 140-179 mg/dL: Increase by 4 units
    • FBG 120-139 mg/dL: Increase by 2 units
    • FBG <100 mg/dL: Decrease by 2-4 units
    • Any hypoglycemia (<70 mg/dL): Decrease by 10-20% 3

Special Considerations

  • For patients with renal impairment: Consider a slightly reduced starting dose due to decreased insulin clearance 3
  • For patients on glucocorticoids: May require higher insulin doses to manage steroid-induced hyperglycemia
  • For patients with history of hypoglycemia: Monitor more closely after conversion

Remember that while the unit conversion is 1:1, individual patient response may vary, necessitating close monitoring and potential dose adjustments after the transition.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Insulin Glargine: a review 8 years after its introduction.

Expert opinion on pharmacotherapy, 2009

Guideline

Managing Nocturnal Hyperglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.